The KRAS mutation has been found to be present in a small percentage of primary bladder adenocarcinomas, is associated with the onset and prognosis of bladder cancer and can be used as a biomarker for bladder cancer surveillance and efficacy evaluation (17–19). This evidence concerns the gene KRAS and urinary bladder carcinoma.